News

Convening of a Shareholders Meeting – August 2017
13/07/2017
The Company hereby announces the convening of an Annual and Extraordinary General Meeting of the Company, to be held at the offices of the Company, on Thursday, August 17, 2017, at 10:00 AM (Israel time). Details regarding the General Meeting (including items on the agenda and voting instructions) can be found here (Hebrew)
Successful completion of the POC program in the Apo-Si technology
11/07/2017
Successful completion of the POC program in the Apo-Si technology
Annual Shareholders Meeting
20/10/2016
Nomination of Professor Roger D. Kornberg, Nobel Prize Laureate in Chemistry for the year 2006, as the Scientific President of the Company
19/05/2016
Nomination of Professor Roger D. Kornberg, Nobel Prize Laureate in Chemistry for the year 2006, as the Scientific President of the Company.
Achieving a milestone in the development of the Apo-Si
24/03/2016
Achieving a milestone in the development of the Apo-Si
Convening of a Shareholders Meeting – Dec 2015
24/12/2015
The Company hereby announces the convening of an Annual and Extraordinary General Meeting of the Company, to be held at the offices of the Company, on Thursday, December 24, 2015 at 4:00 PM (Israel time). Details regarding the General Meeting (including items on the agenda and voting instructions) can be found here (Hebrew)
Aposense has signed a Technology Evaluation Agreement with Pfizer, Inc. in connection with the ML-10 molecule which the Company developed as part of its activities in the field of molecular imaging.
20/09/2015
Aposense has signed a Technology Evaluation Agreement with Pfizer, Inc. in connection with the ML-10 molecule which the Company developed as part of its activities in the field of molecular imaging.
Aposense announces the appointment of Etty Genis as VP finance and COO
07/09/2015
Aposense announces the appointment of Etty Genis as VP finance and COO
PDF
Patent approval for the ATT11T molecule in Japan
25/08/2015
Patent approval for the ATT11T molecule in Japan
Patent approval for the ATT11T in the USA for Pancreas cancer
20/08/2015
Patent approval for the ATT11T in the USA for Pancreas cancer
Patent approval for the ATT11T molecule in China
21/07/2015
Patent approval for the ATT11T molecule in China
Apo-Si presentation publication by Promatheus
16/06/2015
Apo-Si presentation publication by Promatheus
Aposense announces the appointment of Hagit Grimberg as VP R&D
28/05/2015
Aposense announces the appointment of Hagit Grimberg as VP R&D
PDF
Aposense announces the appointment of Yuval Gottenstein as CFO and VP business development
28/05/2015
Aposense announces the appointment of Yuval Gottenstein as CFO and VP business development
PDF
Dov Farkash left his position as acting CEO and CFO
27/05/2015
Dov Farkash left his position as acting CEO and CFO
Aposense announces the appointment of Professor Ilan Ziv as CEO and CSO
27/05/2015
Aposense announces the appointment of Ilan Ziv as CEO and CSO
PDF
Postponement of a Shareholders Meeting - Update
23/09/2014
The Company hereby announces that the Annual and Extraordinary General Meeting of the Company (originally scheduled for September 21, 2014), is postponed to October 7, 2014, at 10:00 AM (Israel time), Details regarding the General Meeting (including items on the agenda and voting instructions)
Patent approval for the ATT11T in the USA for Colon cancer
17/09/2014
Patent approval for the ATT11T in the USA for Colon cancer
Convening of a Shareholders Meeting – Sep 2014
03/09/2014
The Company hereby announces the convening of an Annual and Extraordinary General Meeting of the Company, to be held at the offices of the Company, on Sunday, September 21, 2014, at 10:00 AM (Israel time). Details regarding the General Meeting (including items on the agenda and voting instructions) can be found here (Hebrew)